drugset / Trial / NCT01363037

Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

NCT01363037

Phase 1 Completed 48 enrolled International Partnership for Microbicides, Inc.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to assess the pharmacokinetics of the combination dapivirine and maraviroc vaginal ring and determine whether it is safe when used continuously for 28 days by healthy women in the United States.

Timeline

Start
2011-11
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 100 mg Other
Subject dapivirine Small molecule 25 mg Other